Connolly SJ, Ezekowitz MD, Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation . N Engl J Med. 2009;361(12):1139-1151. DOI:10.1056.NEJM0a0905561. http://www.nejm.org
2.
Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban ver- sus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.
3.
Eikelboom JW , O’Donnell M., Yusuf S., et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment . Am Heart J2010;159(3): 348-353.e1.
4.
Schulman S., Kearon C., Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352.
